Gabriela Leuschner1, Fredrik Reiter2, Florian Stocker2, Alexander Crispin3, Nikolaus Kneidinger2, Tobias Veit2, Friederike Klenner2, Felix Ceelen2, Gregor Zimmermann2, Hanno Leuchte4, Simone Reu5, Julien Dinkel6, Jürgen Behr2, Claus Neurohr2. 1. Department of Internal Medicine V, Comprehensive Pneumology Centre (CPC-M), Member of the German Centre for Lung Research (DZL), Ludwig-Maximilian University Munich, Marchioninistrasse 15, 81377, Munich, Germany. gabriela.leuschner@med.uni-muenchen.de. 2. Department of Internal Medicine V, Comprehensive Pneumology Centre (CPC-M), Member of the German Centre for Lung Research (DZL), Ludwig-Maximilian University Munich, Marchioninistrasse 15, 81377, Munich, Germany. 3. IBE - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilian University Munich, Munich, Germany. 4. Department of Internal Medicine II, Neuwittelsbach Academic Hospital, Ludwig-Maximilian University Munich, Munich, Germany. 5. Institute of Pathology, Faculty of Medicine, Ludwig-Maximilian University Munich, Munich, Germany. 6. Department of Radiology, Comprehensive Pneumology Centre (CPC-M), Member of the German Centre for Lung Research (DZL), Ludwig-Maximilian University Munich, Munich, Germany.
Abstract
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is considered a disease of older patients, being rare in patients ≤ 50 years. Still, IPF can occur in younger patients, but this particular patient group is not well characterised so far. The aim of this study was to compare the diagnostic certainty, clinical features, comorbidities and survival in young versus older IPF patients. METHODS: We reviewed our medical records from February 2011 until February 2015, to identify IPF patients, who were then classified as young (≤ 50 years) or older IPF (> 50 years). Radiographic and histological findings, lung function parameters, comorbidities, disease progression and survival were analysed and compared between the two groups. RESULTS: Of 440 patients with interstitial lung disease, 129 patients with IPF were identified, including 30 (23.3%) ≤50 years and 99 (76.7%) > 50 years. There were no differences between age groups in baseline demographics; younger patients were less likely to have a confirmed diagnosis by high-resolution computed tomography (p = 0.014), more likely to require a biopsy (p = 0.08) and less likely to have received antifibrotic therapy (p = 0.006). Despite an overall limited prognosis, younger patients had a significantly better median survival after diagnosis (p = 0.0375), with a significantly higher proportion of older patients dying due to respiratory failure (p = 0.0383). CONCLUSION: IPF patients under the age of 50 years have similar features and clinical course compared to older IPF patients. These patients should be diagnosed by adopting a multidisciplinary team approach, potentially benefitting from earlier intervention with effective antifibrotic therapy.
INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is considered a disease of older patients, being rare in patients ≤ 50 years. Still, IPF can occur in younger patients, but this particular patient group is not well characterised so far. The aim of this study was to compare the diagnostic certainty, clinical features, comorbidities and survival in young versus older IPFpatients. METHODS: We reviewed our medical records from February 2011 until February 2015, to identify IPFpatients, who were then classified as young (≤ 50 years) or older IPF (> 50 years). Radiographic and histological findings, lung function parameters, comorbidities, disease progression and survival were analysed and compared between the two groups. RESULTS: Of 440 patients with interstitial lung disease, 129 patients with IPF were identified, including 30 (23.3%) ≤50 years and 99 (76.7%) > 50 years. There were no differences between age groups in baseline demographics; younger patients were less likely to have a confirmed diagnosis by high-resolution computed tomography (p = 0.014), more likely to require a biopsy (p = 0.08) and less likely to have received antifibrotic therapy (p = 0.006). Despite an overall limited prognosis, younger patients had a significantly better median survival after diagnosis (p = 0.0375), with a significantly higher proportion of older patients dying due to respiratory failure (p = 0.0383). CONCLUSION:IPFpatients under the age of 50 years have similar features and clinical course compared to older IPFpatients. These patients should be diagnosed by adopting a multidisciplinary team approach, potentially benefitting from earlier intervention with effective antifibrotic therapy.
Entities:
Keywords:
Clinical course; Comorbidity; Idiopathic pulmonary fibrosis; Survival; Young patients
Authors: Justin M Oldham; Ayodeji Adegunsoye; Eleanor Valenzi; Cathryn Lee; Leah Witt; Lena Chen; Aliya N Husain; Steven Montner; Jonathan H Chung; Vincent Cottin; Aryeh Fischer; Imre Noth; Rekha Vij; Mary E Strek Journal: Eur Respir J Date: 2016-04-21 Impact factor: 16.671
Authors: Steven D Nathan; Oksana A Shlobin; Nargues Weir; Shahzad Ahmad; Julienne M Kaldjob; Edwinia Battle; Michael J Sheridan; Roland M du Bois Journal: Chest Date: 2011-07 Impact factor: 9.410
Authors: Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster Journal: Am J Respir Crit Care Med Date: 2006-06-29 Impact factor: 21.405
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: J Behr; A Günther; W Ammenwerth; I Bittmann; R Bonnet; R Buhl; O Eickelberg; R Ewert; S Gläser; J Gottlieb; C Grohé; M Kreuter; C Kroegel; P Markart; C Neurohr; M Pfeifer; A Prasse; N Schönfeld; J Schreiber; H Sitter; D Theegarten; A Theile; A Wilke; H Wirtz; C Witt; H Worth; P Zabel; J Müller-Quernheim; U Costabel Journal: Pneumologie Date: 2013-01-16
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Gregor S Zimmermann; Werner von Wulffen; Patrick Huppmann; Tobias Meis; Franziska Ihle; Jens Geiseler; Hanno H Leuchte; Amanda Tufman; Juergen Behr; Claus Neurohr Journal: Respirology Date: 2014-04-03 Impact factor: 6.424